cagrilintide amylin analog weight loss trial Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for in early trials. The potential benefit Cagrilintide: Mechanism, Effects & Research
Cagrilintide: Mechanism, Effects & Research Studies A new drug combo of semaglutide (GLP 1 receptor agonist) with cagrilintide (amylin analogue) failed to do as well as tirzepatide (GLP 1 GIP receptor agonist). The future of these medicines is hitting different receptors. Cagrilintide produced 10.8 percent body weight loss in 26 weeks in a phase 2 trial. Without touching the GLP 1 pathway. Different mechanism, different lever. Cagrilintide is a long acting amylin analog. Amylin is CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial Cagri Peptide Research Amylin Analog RUO USA
Pay in 4 interest-free payments of $6.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10



